Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers

Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics LONDON, July 13, 2026 /PRNewswire/ -- Halia Therapeutics today announced two posters at the Alzheimer's Association...